)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
CytomX Therapeutics
CytomX Therapeutics (CTMX) investor relations material
CytomX Therapeutics 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary14 Jan, 2026
Strategic Focus and Platform Overview
Emphasis on advances in oncology using the Probody/PROBODY® therapeutic platform, aiming for improved safety and efficacy in cancer treatment.
Integrated R&D capabilities, focused product development, and broad applicability across multiple tumor types and modalities.
Strong business development partnerships with major pharmaceutical companies, including Bristol Myers Squibb, Amgen, Astellas, Regeneron, and Moderna.
Robust cash position with a runway funded into Q2 2027, not including potential milestone payments or new business development.
Vaseta M / Varsetatug masetecan (EpCAM-targeting ADC) Clinical Progress
Phase I study expanded to over 100 patients, with a data update expected by end of Q1 2026.
Interim results in late-line metastatic colorectal cancer showed a 28% confirmed overall response rate, 94% disease control, and 5.8 months progression-free survival.
Favorable safety profile with no classic EpCAM toxicities, no dose-limiting toxicities, and manageable adverse events; main concern is grade 3 diarrhea, addressed with prophylaxis.
Combination study with bevacizumab to start in Q1 2026, targeting earlier lines of therapy and additional tumor types.
Positioned as a first-in-class ADC for a broad EpCAM+ patient population, with potential expansion beyond CRC and a large market opportunity.
CX801 (Probody/PROBODY® IFNα-2b) Development
Designed to localize interferon activity to tumors, reducing systemic toxicity and enhancing immune response.
Early clinical data show strong induction of interferon-regulated genes and T-cell recruitment in melanoma.
No dose-limiting toxicities observed in initial dose escalation; combination with Keytruda/KEYTRUDA® underway.
Initial biomarker data in 2025 and combination data with Keytruda expected by end of 2026.
Aims to address high unmet need in PD-1 refractory melanoma and has potential for broad application in post-immunotherapy solid tumors.
Varseta-M diarrhea prophylaxis impact
CX-801 combination strategy beyond melanoma
Varseta-M registrational dose selection
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next CytomX Therapeutics earnings date
Q4 20255 Mar, 2026
CytomX Therapeutics
Next CytomX Therapeutics earnings date
Q4 20255 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. The company utilizes its proprietary Probody® platform to create antibody-based therapies that target cancer cells while minimizing damage to healthy tissues. CytomX’s approach aims to improve the safety and effectiveness of existing cancer therapies by activating its drugs only in the tumor microenvironment. The company's development pipeline includes therapeutic candidates designed for a variety of cancers, with the goal of addressing unmet medical needs in oncology. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage